HIV with cryptococcal meningitis
Conditions
Interventions
Sponsors
Chongqing Public Health Medical Treatment Center
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >- 18 years, male or female; 2. One of the following situations: (1) HIV antibody positive, confirmed by Western Blot confirmation test; the first diagnosis of cryptococcal meningitis, the diagnosis of cryptococcal meningitis is based on: 1) Symptoms and signs: mainly include low-grade fever, headache, nausea, vomiting, mental state changes, mental confusion, irritability, memory impairment, behavior changes, lethargy, neck stiffness, visual disturbances and other symptoms; 2) Cerebrospinal fluid examination: increased pressure, increased protein content in cerebrospinal fluid, decreased sugar content, mild or moderate leukocytosis in cerebrospinal fluid; 3) Microbiological and immunological examinations: cerebrospinal fluid ink staining showed Cryptococcus, cerebrospinal fluid cryptococcus antigen positive or cerebrospinal fluid cryptococcus positive culture. (2) HIV antibody positive, confirmed by Western Blot confirmation test, blood CrAg negative; (3) HIV antibody negative, blood CrAg negative. 3. Voluntarily participate in this study and sign the informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Those who have received immunomodulatory therapy (such as interleukin, interferon, cyclosporine, etc.) within 60 days before enrollment; 3. Those who have received antibiotics (sulfa, etc.), metformin, probiotics, prebiotics and other drug treatments within 30 days of enrollment; 4. Patients who have participated in study drug treatment within 60 days before enrollment; 5. Gastrointestinal reactions such as diarrhea and abdominal pain occurred before enrollment; 6. Acute or severe disease or infection (such as liver cirrhosis, kidney, jaundice, gastrointestinal bleeding, tumor, etc.) requiring systemic treatment and/or hospitalization within 60 days before enrollment; 7. ALT more than 5 times the normal value, neutrophil count below 500 x 10^6 cells/L, platelet count below 50,000 x 10^6 cells/L, and creatinine level above 220 µmol/L.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in immune cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| Gene model changes and corresponding functional changes;The interplay between immune cells; | — |
Countries
China
Contacts
Public ContactChen Yaokai
Chongqing Public Health Medical Treatment Center
Outcome results
None listed